Antipsychotic-Induced Dopamine Supersensitivity Psychosis: Pharmacology, Criteria, and Therapy
The DOI matches its Crossref record; 220 of the 221 references it cites were found in a registry or an index.
Abstract
The first-line treatment for psychotic disorders remains antipsychotic drugs with receptor antagonist properties at D2-like dopamine receptors. However, long-term administration of antipsychotics can upregulate D2 receptors and produce receptor supersensitivity manifested by behavioral supersensitivity to dopamine stimulation in animals, and movement disorders and supersensitivity psychosis (SP) in patients. Antipsychotic-induced SP was first described as the emergence of psychotic symptoms with tardive dyskinesia (TD) and a fall in prolactin levels following drug discontinuation. In the era of first-generation antipsychotics, 4 clinical features characterized drug-induced SP: rapid relapse after drug discontinuation/dose reduction/switch of antipsychotics, tolerance to previously observed therapeutic effects, co-occurring TD, and psychotic exacerbation by life stressors. We review 3 recent studies on the prevalence rates of SP, and the link to treatment resistance and psychotic relapse in the era of second-generation antipsychotics (risperidone, paliperidone, perospirone, and long-acting injectable risperidone, olanzapine, quetiapine, and aripiprazole). These studies show that the prevalence rates of SP remain high in schizophrenia (30%) and higher (70%) in treatment-resistant schizophrenia. We then present neurobehavioral findings on antipsychotic-induced supersensitivity to dopamine from animal studies. Next, we propose criteria for SP, which describe psychotic symptoms and co-occurring movement disorders more precisely. Detection of mild/borderline drug-induced movement disorders permits early recognition of overblockade of D2 receptors, responsible for SP and TD. Finally, we describe 3 antipsychotic withdrawal syndromes, similar to those seen with other CNS drugs, and we propose approaches to treat, potentially prevent, or temporarily manage SP.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“but concerns [13] have remained about supersensitivity psychosis [9].”
From Acute and Persistent Withdrawal Syndromes Following Discontinuation of Psychotropic Medications (2020) · cites this paper as [9]
In the citing paper
“In the era of first-generation antipsychotics (FGAs) both supersensitivity psychosis and tardive dyskinesia were widely studied [9].”
From Acute and Persistent Withdrawal Syndromes Following Discontinuation of Psychotropic Medications (2020) · cites this paper as [9]
In the citing paper
“Although not widely recognized, withdrawal symptoms can occur on the cessation of both first- and second-generation antipsychotics (FGAs and SGAs).17,20,23”
From A Method for Tapering Antipsychotic Treatment That May Minimize the Risk of Relapse (2021) · cites this paper as [23]
In the citing paper
“Upon the removal of blockade, persistently increased baseline presynaptic DSC in patients with schizophrenia may interact with elevated postsynaptic sensitivity to increase the likelihood of relapse.7,23”
From A Method for Tapering Antipsychotic Treatment That May Minimize the Risk of Relapse (2021) · cites this paper as [23]
In the citing paper
“Chouinard et al. [9] described withdrawal reactions due to antipsychotics dose decrease, discontinuation, or switch and concluded that acute withdrawal symptoms, rebound, and persistent post-withdrawal disorders may occur”
From Acute and Persistent Withdrawal Syndromes Following Discontinuation of Psychotropic Medications (2020) · cites this paper as [9]
10 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
The Brief Psychiatric Rating Scale.
Overall, J. E., & Gorham, D. R. (1962) · Psychological Reports · doi:10.2466/pr0.1962.10.3.799 · Cited by 11,090
(1976) · Medical Entomology and Zoology · Cited by 8,899
Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia
Lieberman, J. A., Stroup, T. S., McEvoy, J. P., Swartz, M. S., Rosenheck, R. A., Perkins, D. O., Keefe, R. S. E., Davis, S. M., Davis, C. E., Lebowitz, B. D., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051688 · Cited by 5,892
Social Origins of Depression: A Study of Psychiatric Disorder in Women.
Schnitzer, P. K., Brown, G. W., & Harris, T. (1980) · Contemporary Sociology · doi:10.2307/2065631 · Cited by 3,053
A permanent change in brain function resulting from daily electrical stimulation
Goddard, G. V., McIntyre, D. C., & Leech, C. K. (1969) · Experimental Neurology · doi:10.1016/0014-4886(69)90128-9 · Cited by 3,052
Leucht, S., Cipriani, A., Spineli, L., Mavridis, D., Örey, D., Richter, F., Samara, M., Barbui, C., Engel, R. R., Geddes, J. R., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(13)60733-3 · Cited by 2,561
Book Review: Measurement and Classification of Psychiatric Symptoms
Priest, R. G. (1975) · Proceedings of the Royal Society of Medicine · doi:10.1177/003591577506800751 · Cited by 2,262
Drug-induced prolongation of the QT interval
Roden, D. M. (2004) · New England Journal of Medicine · doi:10.1056/nejmra032426 · Cited by 1,965
Antipsychotic drug doses and neuroleptic/dopamine receptors
SEEMAN, P., LEE, T., CHAU-WONG, M., & WONG, K. (1976) · Nature · doi:10.1038/261717a0 · Cited by 1,622
Meltzer, H. Y. (2003) · Archives of General Psychiatry · doi:10.1001/archpsyc.60.1.82 · Cited by 1,393
Research works printed but not linked: 1
- 10.2165/1120086-000000000-00000 · doi:10.2165/1120086-000000000-00000
Cited by
Barnes, T. R., Drake, R., Paton, C., Cooper, S. J., Deakin, B., Ferrier, I. N., Gregory, C. J., Haddad, P. M., Howes, O. D., Jones, I., et al. (2020) · Journal of Psychopharmacology · doi:10.1177/0269881119889296 · Cited by 606
“…D2 receptors which has been held to be potentially responsible for breakthrough psychotic relapse in people with schizophrenia on maintenance antipsychotic medication as well as rebound psychosis after abruptly stopping treatment (Chouinard, 1991; Chouinard et al., 2017; Kimura et al., 2016).”
BackgroundPotkin, S. G., Kane, J. M., Correll, C. U., Lindenmayer, J.-P., Agid, O., Marder, S. R., Olfson, M., & Howes, O. D. (2020) · npj Schizophrenia · doi:10.1038/s41537-019-0090-z · Cited by 359
“2a).(33,37) In turn, increases in antipsychotic medication doses to control breakthrough symptoms are thought to lead to further increases in DRD2 density, resulting in increased dopamine supersensitivity, and consequently, the reemergence of symptoms.”
BackgroundResultInfluentialAcute and Persistent Withdrawal Syndromes Following Discontinuation of Psychotropic Medications
Cosci, F., & Chouinard, G. (2020) · Psychotherapy and Psychosomatics · doi:10.1159/000506868 · Cited by 265
Self-citationFava, G. A., Benasi, G., Lucente, M., Offidani, E., Cosci, F., & Guidi, J. (2018) · Psychotherapy and Psychosomatics · doi:10.1159/000491524 · Cited by 209
Association of Aripiprazole With the Risk for Psychiatric Hospitalization, Self-harm, or Suicide
Montastruc, F., Nie, R., Loo, S., Rej, S., Dell’Aniello, S., Micallef, J., Suissa, S., & Renoux, C. (2019) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2018.4149 · Cited by 179
de Leon, J., Ruan, C.-J., Schoretsanitis, G., & De las Cuevas, C. (2020) · Psychotherapy and Psychosomatics · doi:10.1159/000507638 · Cited by 164
A Method for Tapering Antipsychotic Treatment That May Minimize the Risk of Relapse
Horowitz, M. A., Jauhar, S., Natesan, S., Murray, R. M., & Taylor, D. (2021) · Schizophrenia Bulletin · doi:10.1093/schbul/sbab017 · Cited by 157
Leucht, S., Priller, J., & Davis, J. M. (2024) · American Journal of Psychiatry · doi:10.1176/appi.ajp.20240738 · Cited by 117
Wada, M., Noda, Y., Iwata, Y., Tsugawa, S., Yoshida, K., Tani, H., Hirano, Y., Koike, S., Sasabayashi, D., Katayama, H., et al. (2022) · Molecular Psychiatry · doi:10.1038/s41380-022-01572-0 · Cited by 117
“This hypothesis has a backup in animal studies: sustained blockade of D2R with antipsychotics increased D2R density [20, 52].”
BackgroundFava, G. A., Guidi, J., Rafanelli, C., & Rickels, K. (2017) · Psychotherapy and Psychosomatics · doi:10.1159/000480038 · Cited by 93
Lerner, A., & Klein, M. (2019) · Brain Communications · doi:10.1093/braincomms/fcz025 · Cited by 89
“Symptoms may appear 36–96 h or later after drug discontinuation, dose reduction or switch, depending on the drug’s duration of action and last up to 6 weeks (Chouinard et al., 2017).”
BackgroundInfluentialFava, G. A. (2020) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125320970325 · Cited by 84
The clinical role of well-being therapy
Guidi, J., Rafanelli, C., & Fava, G. A. (2018) · Nordic Journal of Psychiatry · doi:10.1080/08039488.2018.1492013 · Cited by 85
“Withdrawal symptoms do not necessarily wane after drug discontinuation and may build into a persistent post-withdrawal disorder [47,48].”
BackgroundIatrogenic Factors in Psychopathology
Fava, G. A., & Rafanelli, C. (2019) · Psychotherapy and Psychosomatics · doi:10.1159/000500151 · Cited by 82
Framer, A. (2021) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125321991274 · Cited by 73
Mental Pain as a Transdiagnostic Patient-Reported Outcome Measure
Fava, G. A., Tomba, E., Brakemeier, E.-L., Carrozzino, D., Cosci, F., Eöry, A., Leonardi, T., Schamong, I., & Guidi, J. (2019) · Psychotherapy and Psychosomatics · doi:10.1159/000504024 · Cited by 70
Polese, D., Fornaro, M., Palermo, M., De Luca, V., & de Bartolomeis, A. (2019) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2019.00210 · Cited by 70
Neuropharmacological effect of risperidone: From chemistry to medicine
Bhat, A. A., Gupta, G., Afzal, O., Kazmi, I. A., Al-Abbasi, F. A., Altamimi, A. S. A., Almalki, W. H., Alzarea, S. I., Singh, S. K., & Dua, K. (2022) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2022.110296 · Cited by 67
Correll, C. U., Brevig, T., & Brain, C. (2019) · BMC Psychiatry · doi:10.1186/s12888-019-2318-x · Cited by 65
Antipsychotic Withdrawal Symptoms: A Systematic Review and Meta-Analysis
Brandt, L., Bschor, T., Henssler, J., Müller, M., Hasan, A., Heinz, A., & Gutwinski, S. (2020) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2020.569912 · Cited by 56
Twenty-year effects of antipsychotics in schizophrenia and affective psychotic disorders
Harrow, M., Jobe, T. H., & Tong, L. (2021) · Psychological Medicine · doi:10.1017/s0033291720004778 · Cited by 57
“, 2017; Leucht & Davis, 2017), a major factor, among multiple other possible factors, that may be contributing to the negative outcomes in patients experiencing long-term antipsychotic treatment is antipsychotic-induced dopamine super-sensitivity psychosis (aiDSP) (Chouinard et al., 2017; Fallon, Dursun, & Deakin, 201…”
BackgroundClozapine discontinuation withdrawal symptoms in schizophrenia
Blackman, G., & Oloyede, E. (2021) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253211032053 · Cited by 62
A Neurodevelopment Approach for a Transitional Model of Early Onset Schizophrenia
Berardis, D. D., Filippis, S. D., Masi, G., Vicari, S., & Zuddas, A. (2021) · Brain Sciences · doi:10.3390/brainsci11020275 · Cited by 63
Dopamine supersensitivity psychosis in schizophrenia: Concepts and implications in clinical practice
Nakata, Y., Kanahara, N., & Iyo, M. (2017) · Journal of Psychopharmacology · doi:10.1177/0269881117728428 · Cited by 53
“The reader is also referred to the recent review by Chouinard et al. (2017) to explore the relevant knowledge gained in animal studies and to see newly proposed DSP criteria that are suitable for the era of atypical antipsychotics.”
BackgroundSelf-citationEffects of Treatment Discontinuation in Clinical Psychopharmacology
Baldessarini, R. J., & Tondo, L. (2019) · Psychotherapy and Psychosomatics · doi:10.1159/000497334 · Cited by 52
Blackman, G., Oloyede, E., Horowitz, M., Harland, R., Taylor, D., MacCabe, J., & McGuire, P. (2022) · Schizophrenia Bulletin · doi:10.1093/schbul/sbab103 · Cited by 48
Antipsychotic-evoked dopamine supersensitivity
Servonnet, A., & Samaha, A. (2019) · Neuropharmacology · doi:10.1016/j.neuropharm.2019.05.007 · Cited by 49
Self-citationRaballo, A., Poletti, M., & Preti, A. (2020) · Psychological Medicine · doi:10.1017/s0033291720004237 · Cited by 48
Crellin, N. E., Priebe, S., Morant, N. J., Lewis, G., Freemantle, N., Johnson, S., Horne, R., Pinfold, V., Kent, L., Smith, R., et al. (2022) · BMC Psychiatry · doi:10.1186/s12888-022-03822-5 · Cited by 55
“These consequences may result from people stopping medication abruptly without clinical supervision, which may increase withdrawal-related adverse effects including ‘supersensitivity’ psychosis and withdrawal-induced relapse [33, 34].”
BackgroundŠagud, M., Tudor, L., Uzun, S., Perković, M. N., Živković, M., Konjevod, M., Kozumplik, O., Ćusa, B. V., Štrac, D. Š., Radoš, I., et al. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00705 · Cited by 44
“Given the pronounced difference (an average of 100–200 mg/per day) in chlorpromazine equivalents between individuals with and without TRS, some of those patients might developed the antipsychotic-induced dopamine suprasensitivity psychosis (DSST).”
BackgroundEmsley, R., Asmal, L., Rubio, J. M., Correll, C. U., & Kane, J. M. (2020) · Schizophrenia Research · doi:10.1016/j.schres.2019.11.025 · Cited by 41
Agid, O., Crespo‐Facorro, B., de Bartolomeis, A., Fagiolini, A. M., Howes, O. D., Seppälä, N., & Correll, C. U. (2024) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2024.04.012 · Cited by 45
Récalt, A. M., & Cohen, D. (2019) · Psychotherapy and Psychosomatics · doi:10.1159/000496734 · Cited by 38
Treatment-resistant schizophrenia: How far have we traveled?
Pandey, A., & Kalita, K. N. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.994425 · Cited by 49
Liu, C., Hsieh, M. H., Chien, Y., Liu, C.-M., Lin, Y., Hwang, T., & Hwu, H. (2023) · Psychological Medicine · doi:10.1017/s0033291723000429 · Cited by 42
“On the other hand, it would be unwise to reduce dose inad-vertently, as dopamine supersensitivity-mediated relapse (Chouinard et al., 2017) and certain antipsychotic-withdrawal syndromes (Horowitz, Murray, & Taylor, 2022b) might mislead to the judgment of higher relapse rates in clinical trials in…”
BackgroundInsights on current and novel antipsychotic mechanisms from the MAM model of schizophrenia
Sonnenschein, S. F., & Grace, A. A. (2019) · Neuropharmacology · doi:10.1016/j.neuropharm.2019.05.009 · Cited by 40
“, 2007), which can produce a state referred to as DA supersensitivity (Fig. 2; Chouinard et al., 2017).”
BackgroundInfluentialCurrent and emerging long-acting antipsychotics for the treatment of schizophrenia
de Filippis, R., Fazio, P. D., Gaetano, R., Steardo, L., Cedro, C., Bruno, A., Zoccali, R. A., & Muscatello, M. R. A. (2021) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2021.1910674 · Cited by 47
Update on novel antipsychotics and pharmacological strategies for treatment-resistant schizophrenia
de Bartolomeis, A., Ciccarelli, M., Vellucci, L., Fornaro, M., Iasevoli, F., & Barone, A. (2022) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2022.2145884 · Cited by 39
“Furthermore, SSP and delayed-onset TRS may share common abnormalities in the postsynaptic D2R density and affinity state, probably as a compensatory mechanism following the continuous D2R blockade performed by typical antipsychotics [18], causing the loss of efficacy of ongoing therapy.”
BackgroundQuetiapine Abuse Fourteen Years Later: Where Are We Now? A Systematic Review
Vento, A. E., Kotzalidis, G. D., Cacciotti, M., Papanti, G. D., Orsolini, L., Rapinesi, C., Savoja, V., Calabrò, G., CASALE, A. D., Piacentino, D., et al. (2019) · Substance Use & Misuse · doi:10.1080/10826084.2019.1668013 · Cited by 36
“affects plasma levels of quetiapine (Chouinard et al., 2017),”
BackgroundRaballo, A., Poletti, M., & Preti, A. (2022) · Psychological Medicine · doi:10.1017/s0033291722001428 · Cited by 42
“, 2020) and dopamine super-sensitivity induced psychosis (Chouinard et al., 2017) as well as artifactual ascription to CHR-P of individuals actually undergoing an unrecognized first episode psychosis contingently mitigated by AP treatment (Raballo & Poletti, 2019; Raballo, Poletti, & Preti, 2020b); in any case, it is…”
BackgroundSecond to none: rationale, timing, and clinical management of clozapine use in schizophrenia
Qubad, M., & Bittner, R. A. (2023) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253231158152 · Cited by 35
Velligan, D. I., Brain, C., Bouérat, L., & Agid, O. (2019) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2019.00584 · Cited by 37
Treatable Hyperkinetic Movement Disorders Not to Be Missed
Méneret, A., Garcin, B., Frismand, S., Lannuzel, A., Mariani, L., & Roze, E. F. (2021) · Frontiers in Neurology · doi:10.3389/fneur.2021.659805 · Cited by 39
Sonnenschein, S. F., Gill, K. M., & Grace, A. A. (2018) · Neuropsychopharmacology · doi:10.1038/s41386-018-0219-1 · Cited by 34
Okubo, R., Okada, M., & Motomura, E. (2024) · Biomolecules · doi:10.3390/biom14091128 · Cited by 39
“The hyperactivation of dopaminergic transmission, including the supersensitivity and upregulation of dopamine D2 receptors, induced by consecutive exposure to D2 receptor antagonistic antipsychotics is the basis for secondary TRS [154,158].”
BackgroundCosci, F., & Chouinard, G. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-813333-0.00007-x · Cited by 41
Self-citationCohen, D., & Recalt, A. (2019) · Psychotherapy and Psychosomatics · doi:10.1159/000496733 · Cited by 28
Targeting NAT10 inhibits osteosarcoma progression via ATF4/ASNS-mediated asparagine biosynthesis
Zou, Y., Guo, S., Wen, L., Lv, D., Tu, J., Liao, Y., Chen, W., Chen, Z., Li, H., Chen, J., et al. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2024.101728 · Cited by 47
Schizophrenia: Antipsychotics and drug development
Remington, G. J., Hahn, M., Agarwal, S. M., Chintoh, A. F., & Agid, O. (2021) · Behavioural Brain Research · doi:10.1016/j.bbr.2021.113507 · Cited by 35
Carli, M., Weiss, F., Grenno, G., Ponzini, S., Kolachalam, S., Vaglini, F., Viaggi, C., Pardini, C., Tidona, S., Longoni, B., et al. (2023) · Current Neuropharmacology · doi:10.2174/1570159x21666230224102318 · Cited by 42
Current Findings and Potential Mechanisms of KarXT (Xanomeline–Trospium) in Schizophrenia Treatment
Azargoonjahromi, A. (2024) · Clinical Drug Investigation · doi:10.1007/s40261-024-01377-9 · Cited by 33
“This supersensitivity can contribute to the persistence of psychotic symptoms even in the presence of antipsychotic treatment [85].”
Ruso‐Julve, F., Pombero, A., Pilar-Cuéllar, F., García‐Díaz, N., Garcia-Lopez, R., Juncal‐Ruíz, M., Castro, E., Díaz, Á., Vázquez-Bourgón, J., García-Blanco, A., et al. (2019) · Translational Psychiatry · doi:10.1038/s41398-019-0647-7 · Cited by 31
The experiences of 585 people when they tried to withdraw from antipsychotic drugs
Read, J. (2022) · Addictive Behaviors Reports · doi:10.1016/j.abrep.2022.100421 · Cited by 31
“6 The types of withdrawal effects that were reported certainly overlap with the ‘classic’ withdrawal symptoms found with other central nervous system drugs (Chouinard et al., 2017).”
BackgroundInfluentialGangadin, S. S., de Beer, F., Wijnen, B. F. M., Begemann, M., van Beveren, N. J. M., Boonstra, N., de Haan, L., Kikkert, M., Koops, S., van Os, J., et al. (2025) · World Psychiatry · doi:10.1002/wps.21315 · Cited by 28
“This supersensitivity may be more pronounced with D2 receptor blockade by high affinity an tag o nists, compared to low affinity antagonists and partial D2 ag o nists 19,20 .”
InfluentialRaballo, A., Poletti, M., & Preti, A. (2023) · Translational Psychiatry · doi:10.1038/s41398-023-02405-6 · Cited by 29
Wunderink, L. (2019) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125319836566 · Cited by 26
“29 32 Up to date, the last word has not been spoken about this issue, as we will see later on.”
BackgroundAmada, N., Akazawa, H., Ohgi, Y., Maeda, K., Sugino, H., Kurahashi, N., Kikuchi, T., & Futamura, T. (2019) · Neuropsychopharmacology Reports · doi:10.1002/npr2.12076 · Cited by 24
Xanomeline-Trospium and Muscarinic Involvement in Schizophrenia
Kidambi, N. S., Elsayed, O. H., & El‐Mallakh, R. S. (2023) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s406371 · Cited by 30
Sonnenschein, S. F., & Grace, A. A. (2020) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2021.1849144 · Cited by 24
Horowitz, M. A., & Moncrieff, J. (2024) · Current Opinion in Psychiatry · doi:10.1097/yco.0000000000000940 · Cited by 23
Pelizza, L., Leuci, E., Quattrone, E., Azzali, S., Paulillo, G., Pupo, S., Poletti, M., Raballo, A., Pellegrini, P., & Menchetti, M. (2023) · Early Intervention in Psychiatry · doi:10.1111/eip.13434 · Cited by 22
“…to consider that current evidence does not allow to fully discard alternative hypotheses on higher rates of transition to psychosis in CHR-P individuals on AP, related to iatrogenic effects of AP (Zhang et al., 2020) and dopamine super-sensitivity induced psychosis (Chouinard et al., 2017).”
BackgroundNardi, A. E., Cosci, F., Balon, R., Weintraub, S. J., Freire, R. C. R., Krystal, J. H., Roth, T. G., Silberman, E. K., Sonino, N., Fava, G. A., et al. (2018) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000908 · Cited by 23
“The significance of this problem is still downplayed, even in treatment guidelines,(23) but there is an increasing awareness of the difficulties associated with the discontinuation of antidepressants, as outlined in scientific reports.(11,12) Antipanic agents appear to alter multiple neurotransmitter systems, includin…”
BackgroundSelf-citationLiu, C.-C., & Takeuchi, H. (2020) · CNS Drugs · doi:10.1007/s40263-019-00682-8 · Cited by 19
Dijkstra, J. M., & Nagatsu, T. (2021) · Journal of Neural Transmission · doi:10.1007/s00702-021-02450-9 · Cited by 28
Taipale, H. T., Tanskanen, A. J., Luykx, J. J., Solmi, M., Leucht, S., Correll, C. U., & Tiihonen, J. (2022) · Schizophrenia Bulletin · doi:10.1093/schbul/sbac039 · Cited by 21
Potkin, S. G., Kane, J. M., Correll, C. U., Lindenmayer, J., Agid, O., Marder, S. R., Olfson, M., & Howes, O. D. (2020) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.18309 · Cited by 23
Dopamine D2 up-regulation in psychosis patients after antipsychotic drug treatment
Thompson, I. A., de Vries, E. F. J., & Sommer, I. E. (2020) · Current Opinion in Psychiatry · doi:10.1097/yco.0000000000000598 · Cited by 21
“[35], who proposed that the chronic use of antipsychotics may increase the total number of dopamine D2 receptors and dopamine D2 high receptors in the striatum, without showing significant changes in the presynaptic dopamine release, synthesis,or reuptake.”
BackgroundIliopoulou, S. M., Tsartsalis, S., Kaiser, S., Millet, P., & Tournier, B. B. (2021) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s334027 · Cited by 18
Zeng, J., Zhang, W., Wu, G., Wang, X., Shah, C., Li, S., Xiao, Y., Li, Y., Cao, H., Li, Z., et al. (2022) · Schizophrenia Bulletin · doi:10.1093/schbul/sbac094 · Cited by 17
Exploration of Treatment-Resistant Schizophrenia Subtypes Based on a Survey of 204 US Psychiatrists
Correll, C. U., Brevig, T., & Brain, C. (2019) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s234813 · Cited by 21
Jen, Y.-W., Hwang, T., Chan, H., Hsieh, M. H., Liu, C., Liu, C., Hwu, H., Kuo, C., Lin, Y., Chien, Y., et al. (2020) · BMC Psychiatry · doi:10.1186/s12888-020-02957-7 · Cited by 20
Clinical Pharmacy in Psychiatry: Towards Promoting Clinical Expertise in Psychopharmacology
Javelot, H., Faria, C. G. F., Vandenberghe, F., Dizet, S., Langrée, B., Maoût, M. L., Straczek, C., Egron, A., Erb, A., Sujol, G., et al. (2021) · Pharmacy · doi:10.3390/pharmacy9030146 · Cited by 19
“Concerning schizophrenia, antipsychotic-induced dopamine supersensitivity psychosis or chronic low-grade peripheral inflammation can lead to treatment resistance [46,47].”
BackgroundLippi, M., Fanelli, G., Fabbri, C., Ronchi, D. D., & Serretti, A. (2022) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000417 · Cited by 21
“A similar mechanism has also been described in the so-called dopamine supersensitivity psychosis, in which a relapse of psychosis may occur after switching to a PDA from a strong FDA (Takase et al., 2015; Chouinard et al., 2017; Kanahara et al., 2020; Russell et al., 2022).”
BackgroundAlternative Diagnostic Models of the Psychotic Disorders: Evidence-Based Choices
Cohen, B. M., Öngür, D., & Babb, S. M. (2021) · Psychotherapy and Psychosomatics · doi:10.1159/000517027 · Cited by 19
Reduced expression of dopamine D2 receptors on astrocytes in R6/1 HD mice and HD post-mortem tissue
Harris, K. L., Mason, S., Vallin, B., & Barker, R. A. (2021) · Neuroscience Letters · doi:10.1016/j.neulet.2021.136289 · Cited by 16
Five year outcomes of tapering antipsychotic drug doses in a community mental health center
Steingard, S. (2018) · Community Mental Health Journal · doi:10.1007/s10597-018-0313-1 · Cited by 15
When, Why and How to Re-challenge Clozapine in Schizophrenia Following Myocarditis
Qubad, M., Dupont, G., Hahn, M., Martin, S. S., Püntmann, V. O., Nagel, E. C., Reif, A., & Bittner, R. A. (2024) · CNS Drugs · doi:10.1007/s40263-024-01100-4 · Cited by 20
“Catatonia and persistent psychotic symptoms appear to be the most common sequelae of abrupt clozapine termination [165, 244, 245].”
BackgroundAntipsychotics are related to psychometric conversion to psychosis in ultra‐high‐risk youth
Preti, A., Raballo, A., Meneghelli, A., Cocchi, A., Meliante, M., Barbera, S., Malvini, L., Monzani, E., & Percudani, M. (2021) · Early Intervention in Psychiatry · doi:10.1111/eip.13158 · Cited by 15
“However, we cannot exclude that for some patients, the prescription of an antipsychotic drug might prompt a sensibilization of the dopamine receptors, which may favour a further rebound of symptoms until conversion to psychosis (Chouinard et al., 2017).”
BackgroundStefanou, M., Vittore, D., Wolz, I., Klingberg, S., & Wildgruber, D. (2020) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2020.00318 · Cited by 17
Kanahara, N., Kimura, H., Oda, Y., Ito, F., & Iyo, M. (2021) · Current Neuropharmacology · doi:10.2174/1570159x19666210125152815 · Cited by 13
Self-citationSchamiloglu, S., Lewis, E., Keeshen, C. M., Hergarden, A. C., Bender, K. J., & Whistler, J. L. (2023) · Biological Psychiatry · doi:10.1016/j.biopsych.2023.03.006 · Cited by 15
“Second-generation antipsychotics (SGAs) are important tools in the management of serious mental illness (SMI), including bipolar disorder, major depressive disorder, schizophrenia, and schizoaffective disorder (1,2).”
Reversal of Dopamine Supersensitivity as a Mechanism of Action of Clozapine
Kim, D. D., Barr, A. M., Honer, W. G., & Procyshyn, R. M. (2018) · Psychotherapy and Psychosomatics · doi:10.1159/000491700 · Cited by 14
Kishi, T., Oya, K., Matsui, Y., Nomura, I., Sakuma, K., Okuya, M., Matsuda, Y., Fujita, K., Funahashi, T., Yoshimura, R., et al. (2018) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s176676 · Cited by 15
“10 This could account for the lack of significant differences in the PANSS total and positive scores in the Japanese study between brexpiprazole 4 mg/day and placebo.”
InfluentialBalcıoğlu, Y. H., Gökçay, H., & Yeşilkaya, Ü. H. (2020) · Clinical Neuropharmacology · doi:10.1097/wnf.0000000000000404 · Cited by 16
Niitsu, T., Hata, T., Nishimoto, M., Hosoda, Y., Kimura, A., Oda, Y., Suzuki, M., Takase, N., Seki, R., Fujita, K., et al. (2020) · Asian Journal of Psychiatry · doi:10.1016/j.ajp.2020.102369 · Cited by 15
Self-citationKimura, H., Kanahara, N., & Iyo, M. (2021) · Behavioural Brain Research · doi:10.1016/j.bbr.2021.113126 · Cited by 17
Self-citationAmada, N., Hirose, T., Suzuki, M., Kakumoto, Y., Futamura, T., Maeda, K., & Kikuchi, T. (2023) · Neuropsychopharmacology Reports · doi:10.1002/npr2.12316 · Cited by 13
Iasevoli, F., Avagliano, C., Altavilla, B., Barone, A., Ciccarelli, M., D’Ambrosio, L., Francesco, D. N., Razzino, E., Fornaro, M., & de Bartolomeis, A. (2018) · Psychiatry Research · doi:10.1016/j.psychres.2018.08.109 · Cited by 14
Continuous Dopamine D2 Receptor Blockade and Long-Term Outcome in First-Episode Schizophrenia
Tiihonen, J., Tanskanen, A. J., Solmi, M., Rubio, J. M., Correll, C. U., Kane, J. M., & Taipale, H. T. (2025) · American Journal of Psychiatry · doi:10.1176/appi.ajp.20240321 · Cited by 14
Continuous versus extended antipsychotic dosing in schizophrenia: Less is more
Servonnet, A., Uchida, H., & Samaha, A. (2020) · Behavioural Brain Research · doi:10.1016/j.bbr.2020.113076 · Cited by 15
Self-citationPsychiatric Comorbidities and Schizophrenia in Youths With Attention-Deficit/Hyperactivity Disorder
Jeon, S. M., Lee, D. Y., Cha, S., & Kwon, J. (2023) · JAMA Network Open · doi:10.1001/jamanetworkopen.2023.45793 · Cited by 19
Kanahara, N., Takase, M., Sasaki, T. G., Honma, M., Fujita, Y., Tadokoro, S., Suzuki, H., Yamanaka, H., Noda, S., Yanahashi, S., et al. (2020) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000322 · Cited by 13
“Tardive dyskinesia is also a characteristic of DSP (Chouinard, 1991; Chouinard and Chouinard, 2008; Chouinard et al., 2017).”
BackgroundSelf-citationAntidepressant Discontinuation Syndrome
Kim, S. H., Kim, Y. S., & Kang, U. G. (2024) · 신경정신의학 · doi:10.4306/jknpa.2024.63.2.104 · Cited by 12
What psychologists need to know about psychotropic medications
Tomba, E., Guidi, J., & Fava, G. A. (2018) · Clinical Psychology & Psychotherapy · doi:10.1002/cpp.2154 · Cited by 11
The emerging role of exosomes in Schizophrenia
Dai, J., Zhang, M., He, Q., & Chen, R. (2023) · Psychiatry Research · doi:10.1016/j.psychres.2023.115394 · Cited by 11
Liu, C., Hsieh, M. H., Chien, Y., Liu, C., Lin, Y., Hwang, T., & Hwu, H. (2021) · Early Intervention in Psychiatry · doi:10.1111/eip.13144 · Cited by 12
“Also, dopamine supersensitivity-mediated relapse during medication discontinuation (Chouinard et al., 2017) might contribute to higher relapse rates in clinical trials in which the dose were reduced much faster than that occurred in naturalistic settings and the criteria of relapse are stricter in…”
BackgroundMethodRaballo, A., Poletti, M., & Preti, A. (2021) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyab030 · Cited by 13
“The reason can be a sensibilization effect on the dopaminergic neurons because of persistent block of the pre- and post-synaptic receptors, causing a hypersensitivity of the neurons to dopaminergic discharge (Chouinard et al., 2017; Nakata et al., 2017; Yin et al., 2017).”
BackgroundStorck, W., de Laportalière, T. T., Yrondi, A., Javelot, H., Berna, F., & Montastruc, F. (2024) · Psychopharmacology · doi:10.1007/s00213-024-06554-4 · Cited by 10
“Indeed, long term treatment with antipsychotics could lead to an increased dopaminergic response after discontinuation (Chouinard et al. 2017).”
Hypersexuality during treatment with cariprazine in a patient with schizophrenia? A case report
Prelog, P. R., & Palandačić, A. K. (2023) · BMC Psychiatry · doi:10.1186/s12888-023-05432-1 · Cited by 12
“Since cariprazine has a similar receptor profile as ari-piprazole, drug-induced dopamine hypersensitivity in schizophrenic patients should also be considered as a part of the differential diagnosis [35].”
BackgroundWisłowska-Stanek, A., Jarkiewicz, M., & Mirowska-Guzel, D. M. (2024) · Pharmacological Reports · doi:10.1007/s43440-024-00689-z · Cited by 18
“Other symptoms are nausea, nightmares, and insomnia [9, 55 ].”
Influential
Metadata
- Authors
- Chouinard, G., Samaha, A.-N., Chouinard, V.-A., Peretti, C.-S., Kanahara, N., Takase, M., & Iyo, M.
- Affiliations
- Hôpital Saint-Antoine (FR)
- McLean Hospital (US)
- Chiba University (JP)
- ORCID
- Venue
- Psychotherapy and Psychosomatics
- Publisher
- S. Karger AG
- Published
- 2017
- Volume
- 86
- Issue
- 4
- Pages
- 189-219
- ISSN
- 0033-3190 (ISSN-L)
- 1423-0348
- OpenAlex
- W2701376032
- Cited by
- 270
- References
- 221
- Citations by year
- 2026: 29 · 2025: 19 · 2024: 32 · 2023: 36 · 2022: 29 · 2021: 39 · 2020: 29 · 2019: 37 · 2018: 17 · 2017: 3
- FWCI
- 3.57
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- karger.com/pages/terms-and-conditions (vor)
- karger.com/pages/terms-and-conditions (tdm)
- Locations
- Psychotherapy and Psychosomatics (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Japan Society for the Promotion of Science (17K10266)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Keywords
- dopamine receptor supersensitivity, tardive dyskinesia, treatment-resistant schizophrenia, psychotic relapse, atypical antipsychotics, long-acting injectable antipsychotics, prolactin, drug-induced movement disorders
- MeSH terms
- Brain, Dopamine, Humans, Psychoses, Substance-Induced, Antipsychotic Agents, Receptors, Dopamine D2, Dopamine D2 Receptor Antagonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.